secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-057018
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Reports Q1 2024 Net Loss of $5.1M and Cash of $36.0M, Advances Pipeline
--------------------------------------------------------------------------------

- Net loss was $5.1M for Q1 2024 vs $2.7M in Q1 2023; R&D expenses rose to $3.1M from $1.2M.
- Cash and cash equivalents totaled $36.0M as of March 31, 2024, providing runway into 2026.
- IND filing for COYA 302 in ALS expected in 2Q24, with Ph. 2 trial initiation thereafter.
- Pipeline expanded to include Frontotemporal Dementia, Parkinson’s, and Alzheimer’s diseases.
- Licensed next-generation immune modulatory biologics from University of Nebraska Medical Center in Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/0000950170-24-057018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/coya-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer